CD274 and Hodgkins lymphoma: Immunotherapy with PD1- and PD-L1-targeted monoclonal antibodies has dramatically changed the therapeutic and prognostic landscape for several types of malignancy including treatment-refractory melanoma [9], non-small cell lung carcinoma [10,11,12,13], renal cell carcinoma [14], and Hodgkin lymphoma [15].